SCHEMBL31168261

SCHEMBL31168261

CC(C)(C)OC(=O)N1CCN(C(=O)Cn2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.51
▸ USP30 Q70CQ3 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ DTYMK P23919 2/20 0.41
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ SCD O00767 1/20 0.38
▸ SCD5 Q86SK9 1/20 0.38
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ HTT P42858 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31168266 1.00 FFAR1 (0.51) FFAR1USP30ALDH1A1MEN1GLA
SCHEMBL31168267 1.00 FFAR1 (0.51) FFAR1USP30ALDH1A1MEN1GLA
SCHEMBL12439731 0.86 FFAR1 (0.50) FFAR1USP30CHRM2CHRM4CHRM1
SCHEMBL15726271 0.85 FFAR1 (0.48) FFAR1USP30CHRM2CHRM4CHRM1
SCHEMBL15377252 0.84 FFAR1 (0.50) FFAR1USP30SCDSCD5USP2
SCHEMBL15416755 0.84 FFAR1 (0.53) FFAR1ALDH1A1KMT2AHTTSMN1; SMN2
SCHEMBL12993498 0.83 FFAR1 (0.49) FFAR1USP30SCDSCD5
SCHEMBL2799598 0.83 USP30 (0.51) FFAR1USP30KDM1A
SCHEMBL992468 0.83 FFAR1 (0.52) FFAR1ALDH1A1CHRM2CHRM4CHRM3
SCHEMBL24779751 0.83 USP30 (0.47) FFAR1USP30ALDH1A1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 — — EP disclosed
EP-4719592-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-04-08 — — EP disclosed
EP-4695239-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-02-18 — — EP disclosed
WO-2025019585-A1 KINASE INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-23 — — WO disclosed
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition CENTENNIAL THERAPEUTICS, LLC 2024-12-12 — — US disclosed
WO-2024249612-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-12-05 — — WO disclosed
WO-2024216034-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition KHK, GCK, HK1 FFAR1 2849/4885USP30 3111/4885ALDH1A1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback